Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders

September 26, 2012

Wellesley, Mass.– According to a new technical market research report, GLOBAL MARKETS FOR TREATMENTS FOR SYNDROMES OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS (PHM118A) from BCC Research (www.bccresearch.com), the global market for treatments for syndromes of progressive ataxia and weakness disorders was valued at nearly $14 billion in 2011 and should reach nearly $15 billion in 2012. Total market value is expected to reach nearly $23.5 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 9.4%.

Progressive ataxia treatments are expected to have a value of $356.4 million in 2012 and $620.7 million in 2017, a CAGR of 11.7%.

Treatments for progressive weakness syndromes should total nearly $14.6 billion in 2012 and $22.8 billion in 2017, a CAGR of 9.4%.

The need for a complete treatment of these diseases has raised many concerns for a huge global patient base. The market for progressive ataxia and weakness disorders is steadily moving toward scientific approaches and novel drug development with the infusion of technological platforms.  This market is expected to grow further in the next five years with the introduction of novel compounds such as BG-12 from Biogen for multiple sclerosis and Catena from Santhera for the treatment of Friedreich’s ataxia. Many discoveries related to protein misfolding, gene mutation and stem-cell therapy have been worked upon. Additionally, biomarkers for early detection of the diseases, although currently not in abundance, still made their ways through to the market. 

This report will help its readers:

• Gain an overview of the current and future characteristics of the global markets for treatments for progressive Ataxia and weakness disorders
• Breakdown revenues by neurodegenerative dysfunction
• Review applications for neurodegenerative disorder treatment and therapy technologies, with emphasis on small-molecule and monoclonal antibodies technology
• Identify the major players in the industry most likely to compete well now and into the future
• Review patent information relevant to the industry.

This study contributes to the areas of market growth in Friedreich’s ataxia, Gerstmann-Straussler-Sheinker disease, Machado-Joseph disease, amyotrophic lateral sclerosis, progressive bulbar palsy, hereditary spastic paraplegia, hereditary neuropathies, and multiple sclerosis.  Pharmaceutical biotechnical companies, research institutes, and physicians will find this study of interest.  

To Contact us, click here  

Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders( PHM118A )
Publish Date: Oct 2012    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.